Drug Delivery Industry
ZHION
The gobal sales for pharmaceutical products have reached 267 billion
dollars and the sales for North America are 149 billion dollars in 1991.

According to a study from Business Communications Company, Inc.
(www.bccresearch.com)   RC-181N The Evolving Drug Industry: New
Strategies, Product Trends, the worldwide drug industry conitnues to
evolve.. By the year 2007 U.S. sales are expected to grow to $345.7
billion, as the market grows at an AAGR (average annual growth rate) of
10% during the forecast period. Here is a summary table of the trends
in drug sales from 2002-2007.

Trends in Drug Sales ($ Billions)2002-2007

                         2000    2001    2002   2007   AAGR %
Ethical drugs (U.S.)          85.8     95.8   102.6  146.8         7.4
Generic Drugs (U.S.)        47.4     52.2     54.3    90.5       10.8
OTC Drugs (U.S.)            37.7     48.5     57.8   108.4      13.4
Domestic Sales (U.S.)      170.9   196.5   214.7   345.7      10.0
International sales            161.1   185.0    203.5  318.0        9.3
Worldwide Sales             332.0    381.5      418.2  663.7      9.7


The data above  are extracted from a study report (RC-181N The
Evolving Drug Industry: New Strategies, Product Trends, August 2002)
prepared by  BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant
Street, Norwalk, CT 06855,  Telephone: (203) 853-4266; ext. 309,  
Email: publisher@bccresearch.com.

DRUG DELIVERY SYSTEMS

Drug delivery system (DDS) is a vehicle for the drug. It is a formulation
or device that delivers drugs to a specific body locations(s) and/or
provides timely release of drug substances. Thus, DDS improves the
efficacy and/or safety of the drug(s) that it carries. Benefits of new DDS
include a competitive edge after expiry of patent, market extension,
drug rescue, reduction of drug development cost and reduction of
healthcare costs.

Some examples:

Pulmonary Drug Delivery System
Metered Dose Inhaler delivers drugs to our body through our pulmonary
systems.

Dermal Drug Delivery System
SMP, solvent microparticle system) is a topical gel to deliver
water-insoluble drugs in a fashion of two stages.

MCA, mucocutaneous absorption system, a water resistant gel providing
sustained drug delivery.

Transdermal Drug Delivery System
3M Latitude Transdermal Drug Delivery System delivers drugs to our
body via our skin.
MacroChem's MacroDerm & SEPA  Opterone, SEPA-enhanced
testosterone


Transmucosal Delivery System
BEMA, a bioerodible muco-adhesive disc, is used to deliver drugs in our
buccal cavity, either local or systemically.

Implant
Atrigel, a biodegradable sustained release implant to deliver drugs,
proteins and peptides in time spans ranging from minutes to months
locally or systemically.

Stent
Cypher drug-eluting stent delivers sirolimus (Rapamune) to treat
coronary artery lesions.

Elan's Products
Cardizem SR - twice-daily, sustained-release ditiazem
Cardizem CD - once-daily, sustained-release diltiazem
Verelan - once-daily, sustained-release verapamil
Verelan PM - modified release, chronotherapeutic verapamil
Theo-Dur - twice-daily, sustained-release theophylline
Naprelan - once-daily, sustained-release naproxen sodium
Avinza - once-daily, novel dual release morphine sulphate
Ritalin LA - once-daily, pulsatile release of methylphenidate
Rapamune - oral tablet form of poorly water soluble compound.

MAJOR PLAYERS IN THE INDUSTRY

ANDRX CORPORATION Engaged in the formulation and commercialization
of controlled-release oral pharmaceuticals utilizing its proprietary drug
delivery technologies.


ALKERMES INC Alkermes, Inc. is applying the tools of biotechnology to
the development of sophisticated proprietary drug delivery systems.
Drug delivery companies apply proprietary technologies to create new
pharmaceutical products based on drugs developed by others. These
products are generally novel, cost-effective dosage forms that provide
any of several benefits including control of drug concentration in the
blood, improved safety and efficacy, improved patient compliance and
ease of use and expanded indications.


AMARIN CORP PLC ADS Ethical Holdings plc is a global pharmaceutical
group which develops innovative pharmaceutical products across a
range of therapeutic areas utilizing its proprietary advanced oral and
transdermal drug delivery technologies.


ATRIX LABORATORIES INC Atrix Laboratories Inc. is engaged primarily in
the research, development and commercialization of a broad range of
medical, dental, and veterinary products based on the proprietary drug
delivery systems. With the acquisition of ViroTex, the company has a
broad-based platform of drug delivery technologies that provides for
parenteral, transmucosal and topical delivery. These patented
technologies have capabilities of delivering small organic molecules,
peptides, proteins, vaccines and natural products.


ALZA CORPORATION A research-based pharmaceutical company with
leading drug delivery technologies. Their delivery technologies are
applied to develop pharmaceutical products with enhanced therapeutic
value for its own portfolio and many pharmaceutical companies.


BENTLEY PHARMACEUTICAL Bentley Pharmaceuticals is a U.S.-based
drug delivery company specializing in the development of products
based upon innovative and proprietary drug delivery systems, which
also has a commercial presence in Europe, where it manufactures,
markets and distributes branded and generic pharmaceutical products.
The company owns rights to certain U.S. and international patents and
related technology covering methods to enhance the absorption of
drugs delivered to biological tissues.


BIOVAIL CORP INTERNAT Biovail Corporation International is a global
integrated pharmaceutical product development company specializing in
the application of advanced oral controlled release delivery
technologies. Biovail's proprietary technologies are used in formulations
which either improve upon conventional dosage forms of existing
products by providing the therapeutic benefits of controlled release or
are generically equivalent to existing once-daily branded products, while
in both instances providing significant cost advantages.


CIMA LABS INC CIMA is a drug delivery company focused primarily on the
development and manufacture of pharmaceutical products based upon
its patented oral drug delivery technologies for marketing by national
and multinational pharmaceutical companies. The company offers
technologies in the fast-dissolve and oral transmucosal areas. OraSolv
and DuraSolv, its premier fast-dissolve technologies, are oral dosage
formulations incorporating microencapsulated active drug ingredients
into tablets which dissolve quickly in the mouth without chewing or
water.


CELLEGY PHARMACEUTICALS Cellegy Pharmaceuticals, Inc. is a specialty
biopharmaceutical company engaged in the development of prescription
drugs and high performance skin care products. The company's products
are all designed for topical application addressing systemic medical
conditions and localized skin diseases and conditions. The company's
most advanced prescription product candidates include Anogesic and
Tostrex. In addition to the prescription product candidates, the company
developed a line of non-prescription cosmeceutical products which will
help reverse the signs of aging.


COLUMBIA LABORATORIES Columbia Laboratories, Inc. is focused on the
development of unique pharmaceutical products that treat female
specific diseases and conditions including infertility, dysmenorrhea,
endometriosis, hormonal deficiencies and the prevention of sexually
transmitted diseases. The company's research in endocrinology has also
led to the development of a product to treat Andropause in men. The
company's products primarily utilize its patented bioadhesive delivery
technology, which consist principally of a polymer, polycarbophil, and an
active ingredient.


CYGNUS INC Cygnus Inc. is engaged in the development and
manufacture of diagnostic medical devices, utilizing proprietary
technologies to satisfy unmet medical needs cost effectively. The
company's current efforts are focused on a frequent, automatic and
non-invasive glucose monitoring device, the GlucoWatch-Registered
Trademark-biographer, and enhancements thereto.


ELAN CORP PLC Elan Corporation, plc is a leading worldwide specialty
pharmaceutical company focused on the discovery, development and
marketing of therapeutic products and services in neurology, acute care
and pain management and on the development and commercialization
of products using its extensive range of proprietary drug delivery
technologies. The company consists of three operating divisions: Elan
Pharmaceuticals, Elan Pharmaceutical Technologies and Elan
Pharmaceutical Operations.


EMISPHERE TECHNOLOGIES Emisphere Technologies is a
biopharmaceutical company focused on the development of a family of
oral heparin products; the application of proprietary synthetic chemical
compounds to serve as "carriers" to facilitate the transport
of therapeutic macromolecules and other compounds across biological
membranes; and the development, in conjunction with the company's
pharmaceutical collaborators, of oral formulations of selected
therapeutic macromolecules.


ETHICAL HOLDINGS LTD ASR Specialist drug delivery groups specializing
in pharmaceutical products utilizing the company's proprietary drug
delivery systems, including oral controlled-release tablets and
transdermal patches.


FLAMEL TECHNOLOGIES SA Engaged principally in the development and
commercialization of controlled-released pharmaceutical products based
upon its two proprietary polymer-based technologies--Micropump, a
microencapsulation technology and Medusa, a nanoencapsulation
technology.


NEKTAR THERAPEUTICS Nektar Therapeutic Systems Inc. is pioneering
drug delivery systems to easily deliver a range of inhaleable drugs,
including peptides, proteins and small molecules, to the deep lung for
treatment of systemic and respiratory diseases. Inhale has developed
the Inhance drug delivery platform that combines innovations in powder
technology and inhalation devices to enable efficient and reproducible
delivery of inhaleable drugs. The company has development
partnerships with several major pharmaceutical and biotechnology
companies. (PRESS RELEASE)


IOMED INC IOMED, Inc. develops, manufactures and commercializes
controllable drug delivery systems using iontophoretic technology.
Iontophoresis is a non-invasive method of enhancing and controlling the
transport of water-soluble ionic drugs into and through the skin using a
low level electrical current. The company's proprietary iontophoretic drug
delivery systems allow rapid onset and cessation of therapeutic action,
as well as programmable dose control.


INSITE VISION INC Insite Vision Inc., is an ophthalmic product
development company focused on developing genetically based tools,
for the diagnosis, prognosis and management of glaucoma, as well as
ophthalmic pharmaceutical products based on our proprietary DuraSite
eyedrop-based drug delivery technology. Their retinal programs include
both therapeutic agents and drug delivery technologies.


K-V PHARMACEUTICAL CL A A recognized leader in the development and
manufacture of major drug products utilizing its proprietary advanced
drug delivery technologies that optimize the benefits of various drug
compounds. Plans to market or co-market other brand name products.


MACROCHEM CORP MacroChem develops pharmaceutical products for
commercialization by applying SEPA (Soft Enhancer of Percutaneous
Absorption), their patented topical drug delivery technology. SEPA
compounds, when properly combined with drugs, provide
pharmaceutical formulations, such as creams, gels and solutions, etc.
that enhance the transdermal delivery of drugs into the skin or into the
bloodstream.


NOVEN PHARMACEUTICALS Noven Pharmaceuticals is a leader in the
development and manufacture of advanced transdermal and
transmucosal drug delivery products and technologies. Noven's principal
commercialized products are transdermal drug delivery systems for use
in hormone replacement therapy. Noven has an active research and
development program with numerous products in development.
Research efforts are focused primarily on four therapeutic categories:
hormone replacement therapy, central nervous system conditions,
cardiovascular disease and pain management.


ANESTA CORP A leader in the development of new pharmaceutical
products for oral transmucosal delivery of systemic drugs. The
Company's proprietary OT drug delivery system is designed to provide
rapid therapeutic action and allows the patient to control drug therapy.


NASTECH PHARMACEUTICALS Nastech Pharmaceutical Co. Inc. is
engaged in the research, development, manufacturing and
commercialization of nasally administered forms of prescription and
over-the-counter pharmaceuticals that are delivered in oral, injectable
or other dosage forms with particular emphasis on treating conditions
mediated by the central nervous system. The nasal delivery of
pharmaceuticals may enable more rapid systemic absorption, quicker
onset of desired effect, and painless, convenient patient
self-administration, resulting in improved compliance and
pharmacoeconomics.


PENWEST PHARMACUTICAL Penwest Pharmaceuticals is engaged in the
research, development and commercialization of novel drug delivery
technologies and has extensive expertise in developing and
manufacturing excipient ingredients for the pharmaceutical industry.
Based on this fundamental expertise in tabletting ingredients, the
company has developed its proprietary TIMERx controlled release drug
delivery technology, which is applicable to a broad range of orally
administered drugs, and ProSolv a co-processing drug delivery
technology platform.


PROVALIS PLC ADS Cortecs Plc is a BioPharmaceutical company
developing new enabling healthcare technologies to assist with the
fight against osteoporosis, diabetes and infectious diseases.


SYMBOLLON CP CL A Engaged in research, development and
commercialization of proprietary iodine-based pharmaceutial agents,
disinfectants, antiseptics and sanitizers.

                                            
HOME
PHARMCEUTICAL
INDUSTRY

Foundamental
Science
Colloidal
Stabilization

Drug Product
Development
Patent Application
Product
Development
Product
Ingredients
Colorant
Scale up a batch 1
Drug Delivery
Industry
Drug Delivery -
Smart Bomb
Lotion, Cream,
Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR
Coating-Aquacoat

Drug Industry
Drug
Competitions
Drug in
Development
Cholesterol-lowering
Drug-Terminologies
Packaging
Materials

Market
Drug Dev- 2004
Drug Dev -
2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market

Novo Norkdisk
R&D

Equipment
Blenders

CONTRACT
MANUFACT.
Nutrition
Supplements

NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Erbitux
(cetuximab)
Gardasil
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm
(Lidocaine)
Liraglutide
Lyrica (pregabalin)
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug
Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2

Double-blind
Study
PHARMCEUTICAL
INDUSTRY

Foundamental
Science
Colloidal
Stabilization

Drug Product
Development
Patent Application
Product
Development
Product
Ingredients
Colorant
Scale up a batch 1
Drug Delivery
Industry
Drug Delivery -
Smart Bomb
Lotion, Cream,
Preps
Enteric
Coating-Eudragit
Enteric
Coating-Nutrateric
SR
Coating-Aquacoat

Drug Industry
Drug
Competitions
Drug in
Development
Cholesterol-lowering
Drug-Terminologies
Packaging
Materials

Market
Drug Dev- 2004
Drug Dev -
2005Q1
Drug Dev- 2005Q2
Drug
Dev-2005Summer
Drug Dev-2005Q3
Orphan Drug
Protein Drug
Niche Market

Novo Norkdisk
R&D

Equipment
Blenders

CONTRACT
MANUFACT.
Nutrition
Supplements

NEW DRUGS
Arranon
Actoplus Met
Alfuzosin
Ambien CR
Avastin
Asmanex(R)
Erbitux
(cetuximab)
Gardasil
GRN163
Herceptin
Increlex (rhIGF-1)
Lidoerm
(Lidocaine)
Liraglutide
Lyrica (pregabalin)
Rozerem
Sorafenib
Sutent
Tamsulosin
Torcetrapib
Zometa
OLD DRUGS
Lithium Carbonate
DRUG NOTES
[CONSTRUCT]
Clinical Research
Terminologies
FDA ALERTS
Protein Drug
Market
Niche Market
Orphan Drug
levothyroxine
Protein Drug 1
Protein Drug2

Double-blind
Study